Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics OfficerJanuary 10, 2022
Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of ResmetiromDecember 30, 2021
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor ConferencesNovember 23, 2021
Press Release History
Resmetirom is an investigational therapy and has not been approved by the FDA (or any other regulatory authority). Resmetirom
is only available for use in a clinical trial setting (ClinicalTrials.gov NCT03900429 and NCT04197479)
Website Developed by Alan Leff Associates, Inc.